We are live on
!
Find out more
Lyell Immunopharma
LYEL
LYEL
117 hedge funds and large institutions have $177M invested in Lyell Immunopharma in 2024 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 31 increasing their positions, 32 reducing their positions, and 20 closing their positions.
New
Increased
Maintained
Reduced
Closed
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
0.11% less ownership
Funds ownership: 2.62% → 2.51% (-0.11%)
3% less repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 32
5% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 20
2% less funds holding
Funds holding: 119 → 117 (-2)
9% less capital invested
Capital invested by funds: $194M → $177M (-$17.4M)
Holders
117
Holders Change
-2
Holders Change %
-1.68%
% of All Funds
1.68%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
19
Increased
31
Reduced
32
Closed
20
Calls
$39K
Puts
–
Net Calls
+$39K
Net Calls Change
+$36K
Top Buyers
| 1 |
Morgan Stanley
New York
|
+$1.88M |
| 2 |
HF
HRT Financial
New York
|
+$836K |
| 3 |
Goldman Sachs
New York
|
+$710K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$484K |
| 5 |
BlackRock
New York
|
+$370K |
